Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the transaction, the executive vice president owned 57,740 shares of the company’s stock, valued at $1,959,118.20. The trade was a 13.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Alkermes Stock Up 3.2%

ALKS opened at $34.96 on Tuesday. The business has a 50 day moving average of $29.96 and a 200-day moving average of $29.42. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $36.45. The stock has a market cap of $5.77 billion, a price-to-earnings ratio of 17.31 and a beta of 0.49.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Assetmark Inc. lifted its stake in Alkermes by 933.8% during the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 747 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Alkermes in the third quarter valued at about $31,000. Salomon & Ludwin LLC raised its position in Alkermes by 115.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after purchasing an additional 667 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Alkermes by 395.6% during the third quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after acquiring an additional 989 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Alkermes in the 2nd quarter worth about $49,000. 95.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

ALKS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Jefferies Financial Group set a $56.00 target price on Alkermes and gave the stock a “buy” rating in a report on Tuesday, October 28th. HC Wainwright reiterated a “neutral” rating on shares of Alkermes in a research report on Wednesday, October 22nd. Wells Fargo & Company lowered their target price on Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a report on Thursday, November 13th. Finally, Royal Bank Of Canada boosted their target price on Alkermes from $45.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.69.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.